Clinical trial Recruiting at 2 sites Interventional Ages 18 to 75

Evaluating the effects of AM3 and probiotics on metabolic syndrome

Official title: A Randomized, Double-blind, Placebo-controlled Pilot Study to Evaluate the Systemic Effect on Immunoinflammatory and Metabolic Status of an Oral Supplementation With AM3 in Patients With Metabolic Syndrome.

Run by Industrial Farmacéutica Cantabria, S.A. · NCT06158152 · Data updated 2026-11-12

This study is testing whether a nutritional supplement with AM3 and probiotics can improve health markers and quality of life for adults with metabolic syndrome.

More Metabolic Syndrome trials

Quick facts

Study typeInterventional
Ages18 Years to 75 Years
SexAll
Enrollment48 (estimated)
SponsorIndustrial Farmacéutica Cantabria, S.A.
Industry-sponsored
Locations2 sites (Madrid and 1 other locations)
StatusRecruiting
StartedMay 20, 2024
Main results expectedNovember 1, 2025
Study endsMarch 1, 2026
Registry record updatedJune 26, 2025
Trial IDNCT06158152 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates are adults aged 18-65 with a diagnosis of metabolic syndrome.

Probably not a fit

Patients with uncontrolled hypertension or those currently using metformin or other conflicting treatments may not benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This pilot study aims to assess the impact of a nutritional supplement combining AM3 and probiotics on inflammatory and metabolic markers in adults diagnosed with metabolic syndrome. A total of 48 participants will be randomized into three groups: one receiving the active supplement, one receiving a placebo, and one receiving AM3 alone. The study will measure various health parameters, including body composition, blood pressure, and biochemical variables, at baseline and after 12 weeks of treatment. Additionally, participants' quality of life will be evaluated through subjective questionnaires.

Why it matters

Potential benefit: If successful, this study could provide a novel dietary intervention to help manage metabolic syndrome and reduce associated health risks.

How similar studies have gone: While there is ongoing research in this area, the specific combination of AM3 and probiotics in this context is relatively novel and has not been extensively tested.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

1. Men or women aged 18-75 years at the time of signing the informed consent form.
2. Diagnosis of metabolic syndrome, defined as: central obesity, elevation of blood glucose by ≥100 mg/dl, glycosylated hemoglobin between 5.7 and 6.4%, low HDL cholesterol levels \< 40 mg/dl in men and \< 50 mg/dl in women, and high levels of triglycerides, being higher than 150 mg/dl.
3. If the patient is being treated with metformin, lipid-lowering treatment with statins or treatment with antihypertensives, he/she must have a stable dose at the time of inclusion.

Exclusion Criteria:

1. Smokers or with history of alcoholism or drug abuse .
2. To have hypertriglyceridemia (\> 500 mg/dL).
3. Uncontrolled arterial hypertension, as per investigator's criteria.
4. To have undergone bariatric surgery over the last 24 months that according to investigator's criteria, this might interfere with his/her participation in the study.
5. Diagnosis of chronic diseases that according to investigator's criteria, this might interfere with his/her participation in the study.
6. Presence of renal insufficiency (glomerular filtration rate below 30 ml/minute).
7. Presence of severe respiratory insufficiency (PaO2 less than 60 mmHg or PaCO2 greater than 50 mmHg).
8. Presence of heart failure (LVEF \<30% and RVEF \<35%).
9. Presence of the following diseases in an unstable manner, according to the investigator's criteria: chronic obstructive disease, inflammatory bowel disease, intestinal malabsorption syndrome, systemic autoimmune diseases, rheumatoid arthritis, spondyloarthritis, psoriasis, and chronic inflammatory skin diseases.
10. Active or chronic severe unstable infections that, in medical criteria, may interfere with patients' safety.
11. Disease-related malnutrition.
12. Endocrinologic unestable or uncontrolled diseases that in medical criteria, present with manifestations in pituitary, adrenal or thyroid function.
13. Immunosuppressive or corticosteroid treatment in the last 3 months.
14. Treatment with semaglutide and tirzepatide.
15. Pregnant women (or intending to become pregnant) or breast-feeding women.

Where it's running

  • Hospital Universitario Infanta Leonor
    Madrid, Spain
    Recruiting
  • Hospital Universitario Príncipe de Asturias
    Madrid, Spain
    Recruiting

Study contacts

  • Principal investigator: Julia Álvarez — Servicio de Endocrinología y Nutrición del Hospital Universitario Príncipe de Asturias de Alcalá de Henares (Madrid)
  • Study coordinator: Ana López-Ballesteros
  • Email: ana.lopez@cantabrialabs.es
  • Phone: +34 671778847

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.